Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 29;13(5):802.
doi: 10.3390/genes13050802.

Molecular Background and Disease Prevalence of Biotinidase Deficiency in a Polish Population-Data Based on the National Newborn Screening Programme

Aleksandra Jezela-Stanek  1 , Lidia Suchoń  2 , Agnieszka Sobczyńska-Tomaszewska  3 , Kamila Czerska  3 , Katarzyna Kuśmierska  4 , Joanna Taybert  2 , Mariusz Ołtarzewski  4 , Jolanta Sykut-Cegielska  2
Affiliations

Molecular Background and Disease Prevalence of Biotinidase Deficiency in a Polish Population-Data Based on the National Newborn Screening Programme

Aleksandra Jezela-Stanek et al. Genes (Basel). .

Abstract

Biotinidase deficiency (BD) is a rare autosomal recessive metabolic disease. Previously the disease was identified only by clinical signs and symptoms, and since recently, it has been included in newborn screening programs (NBS) worldwide, though not commonly. In Europe, BD prevalence varies highly among different countries, e.g., from 1:7 116 in Turkey to 1:75 842 in Switzerland. This paper aimed to present the molecular spectrum of BD (profound and partial forms) in Polish patients diagnosed within the national NBS of 1,071,463 newborns. The initial suspicion of BD was based on an abnormal biotinidase activity result determined in a dry blood spot (DBS) by colorimetric and by fluorimetric methods while biochemical verification was determined by serum biotinidase activity (as quantitative analysis). The final diagnosis of BD was established by serum enzyme activity and the BTD gene direct sequencing. The obtained results allowed for the estimation of disease prevalence (1:66,966 births, while 1:178,577 for profound and 1:107,146 for partial forms), and gave novel data on the molecular etiology of BD.

Keywords: biotinidase deficiency; molecular background; newborn screening.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Pispa J. Animal biotinidase. Ann. Med. Exp. Biol. Fenn. 1965;43:1–39. - PubMed
    1. Wolf B., Grier R.E., Allen R.J., Goodman S.I., Kien C.L. Biotinidase deficiency: The enzymatic defect in late-onset multiple carboxylase deficiency. Clin. Chim. Acta. 1983;131:273–281. doi: 10.1016/0009-8981(83)90096-7. - DOI - PubMed
    1. Cowan T.M., Blitzer M.G., Wolf B. Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee. Technical standards and guidelines for the diagnosis of biotinidase deficiency. Genet. Med. 2010;12:464–470. doi: 10.1097/GIM.0b013e3181e4cc0f. - DOI - PubMed
    1. Sykut Cegielska J. Deficyt biotynidazy—Opis trzech przypadków rozpoznanych po raz pierwszy w Polsce. Klinika. 1993;10:21–23.
    1. Wolf B. The neurology of biotinidase deficiency. Mol. Genet. Metab. 2011;104:27–34. doi: 10.1016/j.ymgme.2011.06.001. - DOI - PubMed

Publication types